Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CCQWD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MM-310
|
|||||
| Synonyms |
MM 310; MM-310; MM310
Click to Show/Hide
|
|||||
| Organization |
Merrimack Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Ephrin type-A receptor 2 (EPHA2)
|
Antigen Info | ||||
| Payload Name |
Docetaxel
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
| TTD ID | ||||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03076372 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors. | ||||
References